molecules-logo

Journal Browser

Journal Browser

Special Issue "Immunoconjugates for Cancer Imaging and Therapy"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: closed (15 August 2020).

Special Issue Editors

Prof. Dr. João Paulo C. Tomé
Website
Guest Editor
Department of Chemical Engineering & CQE, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, nº 1, 1049-001 Lisboa, Portugal 3000
Interests: design and synthesis of functional (photo) active (hybrid) materials based on porphyrins and phthalocyanines for: (i) photomedicine; (ii) photoinduced energy- and electron-transfer materials; (iii) optical (chemo)sensors; and (iv) (photo)catalysis
Special Issues and Collections in MDPI journals
Prof. Jason S. Lewis
Website
Guest Editor
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Dr. Patricia Pereira

Guest Editor
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
Interests: glycoconjugates; immunoconjugates; anti-cancer agents; PET imaging; photodynamic therapy; radiation therapy

Special Issue Information

Dear Colleagues,

Monoclonal antibodies (mAbs), with a high affinity for cancer cell surface antigens, are the most attractive biomolecules as diagnostics and therapeutics in oncology. Since the development of hybridoma technology, in 1975, several antibodies have been developed against either validated or novel tumor antigens overexpressed or selectively expressed on cancer cells.
Antibodies conjugated with drugs incorporate the high affinity/specificity of the mAb with the cytotoxicity of the drug and therefore selectively destroy tumor cells. On the other hand, optical- and radionuclide-labeled antibodies generate images with an intensity proportional to the amount of antibody-targeted tumor-antigen, allowing disease diagnosis and staging, and detection of tumor recurrence.
The present Special Issue on “Immunoconjugates for Cancer Imaging and Therapy” welcomes articles reporting original discoveries and reviews in the context of antibody–drug conjugates and optical- and radionuclide-labeled antibodies to be used as therapeutics and diagnostics in oncology.

Prof. Dr. João Paulo C. Tomé
Prof. Jason S. Lewis
Dr. Patricia Pereira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • drug
  • antigen
  • tumor
  • imaging
  • therapy
  • immunoconjugates

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Molecules 2020, 25(18), 4302; https://doi.org/10.3390/molecules25184302 - 19 Sep 2020
Abstract
Theranostic approach is currently among the fastest growing trends in cancer treatment. It implies the creation of multifunctional agents for simultaneous precise diagnosis and targeted impact on tumor cells. A new type of theranostic complexes was created based on NaYF4: Yb,Tm [...] Read more.
Theranostic approach is currently among the fastest growing trends in cancer treatment. It implies the creation of multifunctional agents for simultaneous precise diagnosis and targeted impact on tumor cells. A new type of theranostic complexes was created based on NaYF4: Yb,Tm upconversion nanoparticles coated with polyethylene glycol and functionalized with the HER2-specific recombinant targeted toxin DARPin-LoPE. The obtained agents bind to HER2-overexpressing human breast adenocarcinoma cells and demonstrate selective cytotoxicity against this type of cancer cells. Using fluorescent human breast adenocarcinoma xenograft models, the possibility of intravital visualization of the UCNP-based complexes biodistribution and accumulation in tumor was demonstrated. Full article
(This article belongs to the Special Issue Immunoconjugates for Cancer Imaging and Therapy)
Show Figures

Graphical abstract

Open AccessFeature PaperArticle
89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
Molecules 2020, 25(10), 2315; https://doi.org/10.3390/molecules25102315 - 15 May 2020
Abstract
High expression levels of the tumor-associated antigen MUC1 have been correlated with tumor aggressiveness, poor response to therapy, and poor survival in several tumor types, including breast, pancreatic, and epithelial ovarian cancer. Herein, we report the synthesis, characterization, and in vivo evaluation of [...] Read more.
High expression levels of the tumor-associated antigen MUC1 have been correlated with tumor aggressiveness, poor response to therapy, and poor survival in several tumor types, including breast, pancreatic, and epithelial ovarian cancer. Herein, we report the synthesis, characterization, and in vivo evaluation of a novel radioimmunoconjugate for the immuno-positron emission tomography (immunoPET) imaging of MUC1 expression based on the AR20.5 antibody. To this end, we modified AR20.5 with the chelator desferrioxamine (DFO) and labeled it with the positron-emitting radiometal zirconium-89 (t1/2 ~3.3 d) to produce [89Zr]Zr-DFO-AR20.5. In subsequent in vivo experiments in athymic nude mice bearing subcutaneous MUC1-expressing ovarian cancer xenografts, [89Zr]Zr-DFO-AR20.5 clearly delineated tumor tissue, producing a tumoral activity concentration of 19.1 ± 6.4 percent injected dose per gram (%ID/g) at 120 h post-injection and a tumor-to-muscle activity concentration ratio of 42.4 ± 10.6 at the same time point. Additional PET imaging experiments in mice bearing orthotopic MUC1-expressing ovarian cancer xenografts likewise demonstrated that [89Zr]Zr-DFO-AR20.5 enables the visualization of tumor tissue—including metastatic lesions—with promising tumor-to-background contrast. Full article
(This article belongs to the Special Issue Immunoconjugates for Cancer Imaging and Therapy)
Show Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview
Antibody–Drug Conjugates for Cancer Therapy
Molecules 2020, 25(20), 4764; https://doi.org/10.3390/molecules25204764 - 16 Oct 2020
Abstract
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while [...] Read more.
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development. Full article
(This article belongs to the Special Issue Immunoconjugates for Cancer Imaging and Therapy)
Show Figures

Graphical abstract

Open AccessFeature PaperReview
Antibody-Targeted Imaging of Gastric Cancer
Molecules 2020, 25(20), 4621; https://doi.org/10.3390/molecules25204621 - 11 Oct 2020
Abstract
The specificity of antibodies for antigens overexpressed or uniquely expressed in tumor cells makes them ideal candidates in the development of bioconjugates for tumor imaging. Molecular imaging can aid clinicians in the diagnosis of gastric tumors and in selecting patients for therapies targeting [...] Read more.
The specificity of antibodies for antigens overexpressed or uniquely expressed in tumor cells makes them ideal candidates in the development of bioconjugates for tumor imaging. Molecular imaging can aid clinicians in the diagnosis of gastric tumors and in selecting patients for therapies targeting receptors with a heterogeneous intratumoral or intertumoral expression. Antibodies labeled with an imaging radiometal can be used to detect primary tumors and metastases using whole-body positron emission tomography (PET) or single photon emission computed tomography (SPECT), both during diagnosis and monitoring disease response. Conjugated with fluorescent dyes, antibodies can image tumors by targeted optical imaging. This review provides an overview of the most recent advances in the use of antibodies labeled with radiometals or conjugated with fluorescent dyes for gastric cancer imaging. Full article
(This article belongs to the Special Issue Immunoconjugates for Cancer Imaging and Therapy)
Show Figures

Figure 1

Back to TopTop